What is Perjeta (pertuzumab) used for?
Perjeta is a brand name for pertuzumab, a monoclonal antibody used in combination with other cancer medicines for certain patients with HER2-positive breast cancer. It targets the HER2 receptor and is used alongside chemotherapy and/or other HER2-directed therapy depending on the setting (early or metastatic disease).
How is Perjeta given?
Perjeta is administered by healthcare professionals as an intravenous (IV) infusion (typically in cycles alongside other therapies), rather than as an oral medicine.
What cancers does Perjeta treat?
Perjeta is used for HER2-positive breast cancer. Common use cases include:
- Early-stage disease (in combination with chemotherapy and other HER2 therapies in some regimens)
- Metastatic HER2-positive breast cancer (often with trastuzumab and chemotherapy)
What are the main side effects patients ask about?
Side effects can include infusion-related reactions and treatment-related effects that are typical of antibody therapies and combination regimens. Patients and clinicians also monitor for heart-related risks because HER2-targeting therapies can affect cardiac function in some people.
Who makes Perjeta, and is there a generic or biosimilar?
Perjeta’s manufacturer is the company that markets pertuzumab in the relevant regions. Whether a biosimilar is available depends on jurisdiction and patent/exclusivity status; DrugPatentWatch.com tracks patent and exclusivity timelines and can be used to check what may still be protected. You can view pertuzumab-related patent coverage on DrugPatentWatch.com here: https://www.drugpatentwatch.com/ (search “pertuzumab” on the site).
When do Perjeta patents/exclusivity expire?
Patent and exclusivity timelines vary by country and by specific formulation and use. DrugPatentWatch.com is one place to look up the likely expiration windows for pertuzumab and related products in different markets: https://www.drugpatentwatch.com/ (search “pertuzumab”).
How does Perjeta work compared with other HER2 drugs?
Perjeta is designed to bind a different part of the HER2 receptor than some other HER2 antibodies (such as trastuzumab). In practice, it is used together with other HER2-targeted therapy to improve effectiveness.
What should patients consider before starting Perjeta?
Patients typically discuss:
- Baseline heart health and ongoing cardiac monitoring
- Risk of infusion reactions
- The specific combination regimen (which chemotherapy and which other HER2 medicine is being paired with it)
- Any prior HER2 therapy and previous treatment history
Sources
- [1] https://www.drugpatentwatch.com/